Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing a role in new developments and the importance of M&A through deals like that of Eli Lilly and Calytr
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
